Objective. To compare the safety and retention rate of TNF antagonists used in approved indications (AIs) and non-AIs.
Introduction
TNFs have a role in the pathogenesis of immune-mediated inflammatory rheumatic conditions, and TNF antagonists have been approved by the European Medicines Agency (EMA) for the treatment of RA, AS, PsA and JIA. A growing number of published reports suggest that TNF antagonists may also be effective in the treatment of conditions outside their currently approved indication (AI) [1] [2] [3] [4] [5] [6] . Concerns regarding off-label use (OU) include applicability, contraindications and precautions of drugs that were developed for a different use. Thus, recommendations have been made to analyse effectiveness and safety of OU drugs [7, 8] .
Registries may pose a potential for analysing the safety of OUs. This is the case of the Spanish registry of adverse events (AEs) of biologic therapies in rheumatic diseases (BIOBADASER 2.0). In the present report, we describe the safety profile and retention rate of OUs of TNF antagonists in >500 patients suffering from a variety of rheumatic conditions. In addition, we aimed to study their safety and retention rates in comparison with RA and AS.
Methods BIOBADASER 2.0 is a national drug safety registry of patients with rheumatic diseases starting treatment with any biologic and followed thereafter. The original registry BIOBADASER was established in February 2000 with 100 centres [9] . BIOBADASER 2.0 is an adaptation of the former made in 2006, which includes all data, since February 2000, from 14 large public hospitals, as a way to reinforce quality and consistency, by facilitating monitoring. Patients entering the registry are followed prospectively and evaluated at the time an AE or a change in the biological therapy occurs; thus providing specific cohorts for specific analyses. The following data are collected online and systematically by participating physicians: (i) data of patients including gender, date of birth, diagnosis, date of diagnosis, comorbidities and risk factors; (ii) data on treatment including types of biologics and dates of initiation and of discontinuation, concomitant treatment for the rheumatic disease and tuberculosis prophylaxis preceding treatment; and (iii) data on AEs, including date of occurrence, type and classification of AE according to the Medical Dictionary for Regulatory Affairs [10] , severity, outcome and concomitant treatments at the time of the AE.
For assessment of the consistency and quality, the database is constantly monitored online and once a year participating units are advised to update the information on all patients. Additionally, a random sample of patients is selected and audited in situ in all 14 centres annually. Starting from January 2008, additional validation of the data was also assured by yearly direct contact with patients by the project managers to confirm whether patients are alive or have been admitted to a hospital for any reason in the preceding year.
The registry protocol and materials of BIOBADASER 2.0 are available at http://biobadaser.ser.es/biobadaser/ eng/index.html and were approved by the Ethics Review Committee of the Hospital Ramon y Cajal (Madrid, Spain) acting as reference committee. Starting from January 2008, all patients signed an informed consent that includes an agreement to be contacted by a member of the registry team to gather medical information, performed according to the principles of the latest Helsinki recommendations and complying with the Spanish regulations for data protection and research.
Study groups and definitions
AIs and OUs of biologics have been registered in BIOBADASER 2.0 since its launch. All adult patients with a diagnosis included in one of the study groups in whom a TNF antagonist was used were included in the analysis.
Patients were classified into AIs and OUs according to the present EMA AIs. AIs include RA, AS and PsA. JIA patients were not included in this analysis as age is a confounder for AEs and the total number of children with JIA followed in the participating hospitals in BIOBADASER 2.0 was low. OU was classified into: (i) chronic arthritis consisting of undifferentiated spondyloarthritis, enteropathic arthritis, seronegative chronic polyarthritis, seronegative chronic oligoarthritis, Still's disease, juvenile uSpA, ReA, Sapho's syndrome and juvenile AS; and (ii) chronic immune-mediated diseases (CIDs) including Behç et's disease, uveitis without rheumatic disease, vasculitis, SLE, PM/DM, sarcoidosis, relapsing polychondritis, SS and SSc.
Exposure
Time of exposure is considered from the beginning of therapy with a TNF antagonist to date of the last administration plus twice the half-life of the TNF antagonist (3 days for etanercept, 2 months for infliximab and 14 days for adalimumab). Observation spans from entry in the cohort (beginning of TNF antagonist date) to censor date (last visit in a lost-to-follow-up patient or discontinuation treatment date), death or 9 October 2009, whichever occurred first. Only the first treatment was considered in the analysis.
Statistical analyses
Continuous variables are expressed as mean (S.D.) and categorical variables are expressed as total with percentages. The population is described using descriptive statistics indicated by the distribution of variables.
The probability of discontinuation from any cause of interest was calculated using Kaplan-Meier survival curves, and a log-rank test was performed stratifying patients by study group for comparison. In patients discontinuing treatment, the cumulative incidence function [11] of cause k (inefficacy, AE or other cause) defined by the probability, Prob (T 4 t, F = k), of failing from cause k before time t, was also estimated, competing risks being the other reasons. Multivariate cause-specific Cox regression models adjusted by sex, age at treatment start and disease duration were used to measure the association between study groups, stratifying patients by reason for discontinuation. An analysis of correspondence with symmetric normalization was performed to examine whether the reason for discontinuation of TNF antagonists differed substantially in AIs and OUs.
Incidence rate (IR) of AE per 1000 patient-years of exposure with 95% CI was calculated in patients with RA, AS, PsA, CA and CID. IR ratios (IRRs) with 95% CI were obtained from generalized linear models with Poisson's distribution, and were adjusted by sex, age at treatment start and disease duration. As infliximab was the most widely used TNF antagonist, we performed separated estimations for infliximab. All analyses were done with Stata 10.1 (Stata Corp., College Station, TX, USA).
Results
Characteristics of the included patients are depicted in Table 1 . Overall, 5150 patients were included, 4594 (89%) of whom were treated with TNF antagonists in AIs and 556 (11%) outside AIs. Among the patients with OUs, 437 suffer from CA and 119 from CID. Patients with CA and CID were younger and had shorter disease duration than the others. Gender distribution was uneven as expected. RA and CID patients were more commonly female, whereas CA, AS and PsA patients were more commonly male. Infliximab was the leading TNF antagonist used in AI and OU. Adalimumab was sparsely used off label. More than two-thirds of the patients in the CID group received CSs concomitant with the TNF antagonists, whereas only one-third of the patients in the CA group were treated with this drug (Table 2) .
All AEs and specific events individually (Table 3) were more common in CID than in other groups, followed by CA and RA, with large and statistically significant IRR for both OU groups compared with RA or AS. This is mainly related to an excess of 'infections and infestations', and of 'general disorders and administration site conditions' in OU. AS patients have a significantly lower IRR of AEs compared with RA, crude and adjusted by gender, age and disease duration. As infliximab is the most widely used TNF antagonist in OU, we performed separated estimations for infliximab (Table 4) and similar results were achieved.
Retention rate curves ( Fig. 1 ) were statistically different (P < 0.0001, log-rank test) between uses of TNF antagonists and demonstrated the highest survival in patients with AS and the lowest in CID. Cause-specific analysis for discontinuation (Table 5) showed a larger hazard ratio (HR) for CID compared with RA and AS in part due to a larger HR for discontinuation for AEs. The HR for discontinuation for CA was significantly larger than for AS but not for RA. The analysis by infliximab use demonstrated only a larger HR for discontinuation for both CA and CID compared with AS. CA has a lower HR for discontinuation compared with RA. Cumulative incidence curves (Fig. 2) show a similar pattern in RA to that in CID, and also similarity between AS and CA. The correspondence analysis (data not shown) had very low total inertia, and very low contribution of the specific categories, disease and reason for discontinuation, and therefore could not show a clear pattern of association between different reasons for discontinuation and AIs or OUs.
Discussion
This study is a description of the safety profile of the OU of TNF antagonists in patients included in a registry of rheumatic diseases. The spectrum of patients treated off label with TNF antagonists in our study seems to correspond to current practice, and is similar to the uses reported in other settings [12] . Overall, the safety profile of OU TNF antagonists in diseases characterized primarily by chronic inflammatory arthropathy was similar to that of SpA, whereas the profile in patients with chronic inflammatory conditions was in general comparable to that of RA. Patients may benefit from off-label prescribing supported by sound scientific and medical evidence. TNF may have a role in the pathogenesis of several chronic inflammatory conditions and inhibition of TNF outside the current AIs has been done in patients resistant to standard treatments in inflammatory myopathies [1] , skin diseases [2, 3] , multisystem sarcoidosis [4] , ANCA-associated systemic vasculitis [6] and many other autoimmune disorders [5, 12] . Off-label prescribing presents a challenge as well as an opportunity involving Adjusted by gender, age at treatment start and disease duration. *P < 0.05; **P < 0.01; ***P < 0.001. 498 (17) 17 (2) 82 (10) 20 (5) 2 (2) effectiveness and safety. A review of OU of biologics in rheumatic diseases indicates that the best results have been observed with the use of rituximab for SS, lupus and cryoglobulinaemia; infliximab for sarcoidosis and adult-onset Still's disease; and etanercept for Behç et's disease, albeit not for uveitis [12] . Reference to safety was included in the review, but non-comparative data were presented. The overall conclusion from our study is that patients treated with TNF antagonists for CID are at high risk of developing toxicity and the opposite for AS and related diseases. Also, the rate of discontinuation follows a similar pattern. In our study, most of the CA patients treated with TNF antagonists outside the AIs were within the spectrum of SpA. Thus, it is not surprising that their safety profile and discontinuation of TNF antagonists mimics that of AS Adjusted by gender, age at treatment start and disease duration. *P < 0.05; **P < 0.01; ***P < 0.001. and of PsA. Furthermore, the majority of patients were treated with infliximab, suggesting that not only the safety but also the efficacy of this biologic in all forms of SpA may be alike. On the other hand, in CID, the pattern of discontinuation was somewhat similar to RA and characterized by a higher discontinuation rate and high infection rate. In RA, severity of disease, extra-articular manifestations, increasing age and CS therapy are independently associated with infection. In lupus, scleroderma and PM/ DM, the risk of severe infections and opportunistic infections is increased and related to the use of CSs and/or immunosuppressors [13] [14] [15] [16] [17] . In our study, two-thirds of the CID patients treated with TNF antagonists were also receiving CSs, thus providing a clue for the high incidence of infections. Also, we found a significant risk of infection in RA patients treated with TNF antagonists. It is likely that CID patients with more severe disease were treated with TNF antagonists, confounding the effect of the disease severity itself and the treatment. Unfortunately, it is very difficult to measure horizontally the disease severity in all patients when diagnoses vary, one of the caveats of a universal drug registry, not a disease-related one. As a matter of fact, BIOBADASER 2.0 only includes a baseline measure of disease activity for RA (namely the DAS-28), AS (BASDAI) and now lupus (SLEDAI).
The rate of discontinuation of TNF antagonists in Still's disease was higher than in RA. Still's disease is nowadays viewed as a systemic autoinflammatory syndrome rather than an immune-mediated chronic inflammatory disease [18] . Rates of AEs and of medically serious infections in JIA including systemic JIA (Still's disease) treated with etanercept range between 6.0 and 7.1, and 1.8 and 2.1, respectively [19] . These numbers are smaller than that reported in Still's disease. However, our patients with Still's disease with a mean age of $40 years represent a population of adult disease perhaps different from the juvenile form. Nevertheless, efficacy of blocking TNF in Still's disease is disputed, and furthermore recent publications show a significant improvement with IL1-Ra [20] [21] [22] [23] or IL-6R antibody treatment [24, 25] . This indicates that the risk/benefit ratio of TNF antagonists in Still's disease does not support their use at the present time.
Our study has some limitations and strengths. Comparison of retention rates across AI and OU of TNF antagonists is troublesome. In RA, AS and PsA, long-term treatment is commonplace and retention rate mirrors effectiveness, whereas no indication regarding length for off-label treatments exists. A decision is based on physicians' opinion, restraining the comparison of effectiveness. This should not have an impact on the profiles of safety as described here. Other constraints could be the relevance and consistency of the information. Information in this article was gathered from the Spanish registry BIOBADASER 2.0, where the study cohort is large, with long-term follow-up, and representative of clinical practice in Spain [26, 27] . The quality and consistency of data were assured by a clear definition of its aim, an optimized number of variables and an easy method of data collection that allowed for consistency checks. All reason for discontinuation (inefficacy, AE and others). *P < 0.05; **P < 0.01; ***P < 0.001.
In addition, BIOBADASER 2.0 data were validated by calling and checking with the patients, and in situ audits. Information was found to be accurate in 92.6% of the cases, and all inconsistencies and missing data were amended. This consistency, valuable for data interpretation, strengthens the relevance of the present work.
In summary, our study shows an additional value of a national registry. Using data from the Spanish registry BIOBADASER 2.0, we were available to describe the safety profile of OUs of TNF antagonists in rheumatic conditions in comparison with other AIs. This information is critical for the evaluation of the risk/benefit ratio of medications used outside AIs.
Rheumatology key messages
. The safety profile of TNF antagonists used off-label in CIDs is similar to RA. . The OUs of TNF antagonists must be closely followed to evaluate the risk/benefit ratio. 
